Last $117.43 USD
Change Today -3.09 / -2.56%
Volume 3.3M
VRX On Other Exchanges
Symbol
Exchange
Toronto
New York
Frankfurt
As of 8:04 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

2150 St. Elzéar boulevard West

Laval, QC H7L 4A8

Canada

Phone: 514-744-6792

Fax: 514-744-6272

Valeant Pharmaceuticals International, Inc. operates as a multinational, specialty pharmaceutical and medical device company. The company develops, manufactures, and markets a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in approximately 100 countries. Its product portfolio comprises approximately 1,500 products. Segments The company operates through two segments, Developed Markets and Emerging Markets. DEVELOPED MARKETS This segment consists of sales in the U.S. of pharmaceutical products, OTC products, and medical device products, as well as alliance and contract service revenues, in the areas of eye health, dermatology and podiatry, aesthetics, and dentistry; sales in the U.S. of pharmaceutical products indicated for the treatment of neurological and other diseases, as well as alliance revenue from the licensing of various products that the company developed or acquired; and pharmaceutical products, OTC products, and medical device products sold in Canada, Australia, New Zealand, Western Europe, and Japan. Pharmaceutical Products The company’s principal pharmaceutical products are: An Acne franchise, which includes Solodyn, a prescription oral antibiotic approved to treat only the red, pus-filled pimples of moderate to severe acne in patients 12 years of age and older, as well as Ziana, Acanya, and Atralin. Wellbutrin XL, an extended-release formulation of bupropion indicated for the treatment of major depressive disorder in adults. Xenazine is indicated for the treatment of chorea associated with Huntington’s disease. In the U.S., Xenazine is distributed for the company by Lundbeck Inc. under an exclusive marketing, distribution, and supply agreement. Zovirax Cream and Zovirax Ointment are prescription topical antivirals, which are active against herpes viruses. Zovirax Cream is indicated for the treatment of recurrent herpes labialis (cold sores) in adults and adolescents (12 years of age and older). Zovirax Ointment is indicated for the management of initial genital herpes. The Lotemax franchise was acquired as part of the acquisition of Bausch & Lomb Holdings Incorporated (B&L) in 2013 (the ‘B&L Acquisition’) in 2013. Lotemax Gel is a topical corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery. The gel formulation was launched in 2013. This new formulation is a technology that allows the drug to adhere to the ocular surface and offers dose uniformity, which eliminates the need to shake the product to ensure the drug is in suspension, a low concentration of preservative, and two known moisturizers. Arestin (minocycline hydrochloride) is a subgingival sustained-release antibiotic. Arestin is indicated as an adjunct to scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis. Arestin might be used as part of a periodontal maintenance program, which includes good oral hygiene and SRP. Prolensa, acquired as part of the B&L Acquisition, is a non-steroidal anti-inflammatory ophthalmic solution for the treatment of inflammation and pain following cataract surgery. OTC Products The company’s principal OTC products are: PreserVision, acquired as part of the B&L Acquisition, is an antioxidant eye vitamin and mineral supplement. ReNu Multiplus, acquired as part of the B&L Acquisition, is a sterile, preserved solution used to lubricate and rewet soft (hydrophilic) contact lenses. ReNu Multiplus product contains povidone, a lubricant that could be used with daily, overnight, and disposable soft contact lenses. Ocuvite, acquired as part of the B&L Acquisition, is a lutein eye vitamin and mineral supplement that contains lutein (an antioxidant carotenoid), a nutrient that supports macular health by helping filter harmful blue light. Artelac, acquired as part of the B&L Acquisition, is a solution in the form of eye drops to treat dry eyes caused by chronic tear dys

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRX:US $117.43 USD -3.09

VRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $241.81 USD +3.88
Astellas Pharma Inc ¥1,601 JPY +17.00
Mylan Inc/PA $47.36 USD -1.07
Shire PLC 5,290 GBp -30.00
Sun Pharmaceutical Industries Ltd 807.15 INR +2.10
View Industry Companies
 

Industry Analysis

VRX

Industry Average

Valuation VRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.3x
Price/Book 7.6x
Price/Cash Flow 60.5x
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VALEANT PHARMACEUTICALS INTE, please visit www.valeant.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.